Colistin, Carbapenem and Cephalosporin-resistant Klebsiella pneumoniae reported from Misrata, Libya by Shallouf, Mohamed et al.
Carbapenem Resistance Expressed by Gram-negative 
Bacilli Isolated from a Cohort of Libyan Patients 
 
Mohamed Shallouf, Pedro MDS Abrantes, Charlene WJ Africa 
 
Microbial Endogenous Infections (MEnIS) Research Laboratories, Department of Medical 







We gratefully acknowledge the FIDSSA for making the conference attendance possible. We also 
would like to acknowledge Dr. Taher Elhobgy, Dr. Mohamed Elfagieh and the Medical Laboratory 
staff at Al-hekma Hospital, Misrata Central Hospital, Misrata Cancer Centre for granting us the use 
of their facility and  helping us in collecting the clinical isolates. 
Aim of study 
Colistin, Carbapenem and Cephalosporin-resistant Klebsiella 
pneumoniae reported from Misrata, Libya 
Klebsiella pneumoniae is a significant human pathogen causing community and nosocomial infection. The use of carbapenem has 
increased since the spread of extended-spectrum β-lactamase (ESBL) resulting in the emergence of carbapenem resistant               
K. pneumoniae (CRKP). Due to the continued use of colistin for treatment of infections by CRKP, resistance to colistin has also 
been reported in several countries and become a major public health concern. 
Introduction 
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The aim of this study was to investigate the prevalence of 
carbapenem, cephalosporin and colistin  resistant K. pneumoniae in 
Libyan patients from Misrata City by investigating their phenotypic 
characteristics and antibiograms. 
 
Background: National surveillance of antimicrobial resistance has become a mandatory approach to control the spread of antimicrobial resistance and for the establishment of antibiotic treatment 
guidelines. In this study, clinical isolates of K. pneumoniae were phenotypically investigated for the presences of Colistin and beta-lactams resistance. 
Methods: Clinical samples were obtained from hospitalised (n=140) and non-hospitalised patients (n= 60) in Misrata, Libya. Identification of the isolated species was achieved using VITEK 2 compact 
system. Screening for Carbapenem and Cephalosporin-resistance was performed using the disk diffusion method with Carbapenem (10µg) and Cephalosporin (30 µg) disks and Minimum Inhibitory 
Concentration (MIC) determined by VITEK 2.  Colistin resistance was determined using both Sensititre Gram-negative Xtra plate format (GNX2F) and VITEK 2. Carbapenememase activity was detected 
using the RAPIDEC CARBA NP, Modified Hodge test, Carbapenem inactivation method, MAST Combi Carba plus kit (D73C) and Meropenem combined disk test. ESBL and AmpC production was 
confirmed using Sensititre ESBL confirmatory plates (ESB1F), modified double disc synergy test MDDST, MAST ESBL detection kit D67C, AmpC & ESBL detection kit D68C along with AmpC 
detection kit D69C.  
Results and conclusion: Of the 200 clinical isolates, 85 (42.5%) were K. pneumoniae of which 54  (63.52%) demonstrated resistance to at least one of the Carbapenems, 16 (18.82%) were ESBL or AmpC 
producers and 2 (2.35%) were Carbapenem and Colistin resistant. 13 (21.25%) isolates were susceptible to all antibiotics tested except Ampicillin and Augmentin. 
Detection of ESBL production 








AMI 55 (64.70) 14 (6.47) 16 (18.82) 
GEN 25 (29.41) 6 (7) 54 (63.52) 
TOB 22 (25.88) 16 (18.82) 47(55.29) 
ETP 33 (38.82) 6 (7) 46 (54.11) 
MER 46 (54.11) 4 (4.70) 35 (41.17) 
IMI 38 (44.70) 18 (21.17) 29 (34.11) 
FEP 15 (17.64) 14 (16.47) 56 (65.88) 
FOT 17 (20) 5 (5.88) 63 (74.11) 
TAZ 20 (23.52) 8 (9.41) 57 (67) 
FOX 27 (31.76) 2 (2.35) 56 (65.88) 
CXM 13 (15.29) 0 (0) 72 (84.70) 
CIP 22 (25.8) 8 (9.41) 58 (68.23) 
SXT 48 (56.74) 1 (1.17) 36 (42.35) 
AUG 0 (0) 0 (0) 85 (100) 
AMP 0 (0)  0 (0) 85 (100) 
P/T 13 (15.29) 8 (9.41) 64 (75.29) 
COL** 83 (97.64) 0 (0) 2 (2.5) 
TGC** 85 (100) 0 (0) 0 (0) 
Table 1, Susceptibility rates of 85  K. pneumoniae isolates 













Figure 1. Specimen Source of 200 Clinical  Isolates. 
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AMI; Amikacin, GEN: Gentamicin; TOB: Tobramycin; ETP; Ertapenem; MERO: Meropenem; IMI: Imipenem; 
FEP;  Cefepim; FOT: Cefotaxime; TAZ; Ceftazidime; FOX: cefoxitin; CXM: cefuroxime; CIP: Ciprofloxacin; 
SXT: Trimethoprim/Sulphamethoxazole; AUG: augmentin; AMP: ampicillin; P/T: Piperacillin/ tazobactam; 
COL: Colistin ; TGC: Tigecycline. ** EUCAST breakpoints 
Figure 2. Distribution of Colistin and Beta-lactam 
resistance mechanisms 
Figure 3. Distribution of various types of 
Carbapenemases 
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Carbapenem S, Cefoxitin R 
Detection of ESBL 
Carbapenem R 
MIC by VITEK using current CLSI and EUCAST breakpoints 
Carbapenem S, Cephalosporine R 
Confirmation of identification using VITEK2 Compact 
Reduced susceptibility 
Screening for resistance:   Carbapenems 10µg Cephalosporins 30µg, and Cefoxitin 30µg 
Colistin R 










D68C D68C D69C 
Detection of AmpC Detection of Colistin resistance 
AXO: ceftriaxone; MERO: meropenem; CEP: cephalothin; POD: cefpodoxime; 
CIP: ciprofloxacin; FOT: cefotaxime; GEN: gentamicin; F/C: cefotaxime/clavulanic 
acid; AMP: ampicillin, TAZ: ceftazidime; FAZ: cefazolin; T/C: ceftazidime/ 
clavulanic acid; IMI: imipenem; P/T4 piperacillin/tazobactam; FEP: cefepime; 

































































FOT 1 FOT 2 FOT 4 FOT 8 FOT 16 FOT 32 
TAZ 1 TAZ 2 TAZ 4 TAZ 8 TAZ 16 
POL 0.25 POL 0.5 POL 1 POL 2 POL 4 
COL 0.25 COL 0.5 COL 1 COL 2 COL 4 
DOR 0.12 DOR 0.24 DOR 0.5 DOR 1 DOR 2 
TGC 0.25 TGC 0.5 TGC 1 TGC 2 TGC 4 TGC 8 
ETP 0.25 ETP 0.5 ETP 1 ETP 2 ETP 4 





IMI: Imipenem; MERO: Meropenem; DOR; Doripenem; ETP; Ertapenem; AMI; Amikacin; 
AZT; Azteroname; TAZ; Ceftazidime; FEP;  Cefepim; P/T4: Pipracillin/ tazobactam;  TIM2: 
Ticarcillin/Clavulanic acid; DOX: Doxycycline; MIN: Minocycline; TGC: Tigecycline; GEN: 
Gentamicin; CIP: Ciprofloxacin; TOB: Tobramycin; LEVO: Levofloxacin; SXT: 
Trimethoprim/Sulphamethoxazole; COL: Colistin, POL: Polymixin B; FOT: Cefotaxime; POS: 
Positive control.  
AXO 1 AXO 2 AXO 8 AXO 4 AXO 16 AXO 32 AXO 64 AXO 128 MERO  1 MERO  2 MERO  4 MERO  8 
CEP 8 CEP 16 POD 0.25 POD 0.5 POD 1 POD 2 POD 4 POD 8 POD 16 POD 32 CIP 1 CIP 2 
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 Establishing infection control programmes, and antibiotic therapy 
guidelines are urgently needed to limit the spread of these organisms. 
 
 The result of this study calls for: 
  increased vigilance  
 accurate screening including the application of molecular 
techniques 
 accurate susceptibility testing  
 continuous surveillance 
 restricted use of antibiotics 
Results 
 Coexistence of carbapenem resistance and colistin 
resistance was observed  for the first time in Libya.   
                                                                                                                                   
 The high rate (65.88) of carbapenem resistance was 
detected only in isolates obtained from in-patients, while 
ESBL and AmpC producers where found in both in-and 
out-patients. 
 
 Among the carbapenemases detected in this study, OXA-
48 was the most predominant type. 
 
 All the isolates showed 100% susceptibility to tigecycline, 
and 100% resistance to ampicillin and augmentin. 
 
54, (65%) 
ESBL, 14 (20%) 
AmpC, 1 (1%) 
AmpC/ESBL, 1 (1%) 
CRKP/Colistin R, 
2(3%) 
